Hepatitis Monthly

Published by: Kowsar

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani 1 , * , Babak Haghpanah 2 , Ali Reza Sayyah 2 , Ali Asad Hashtroudi 2 , Mohammad Bashashati 2 , Parisa Poursamimi 2 and Mehri Nikbin 2
Authors Information
1 Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), nebrahim@sina.tums.ac.ir, Tehran, IR.Iran
2 Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, IR.Iran
Article information
  • Hepatitis Monthly: 4 (7); 71-74
  • Article Type: Research Article

To Cite: Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial, Hepat Mon. Online ahead of Print ; 4(7):71-74.

Abstract
© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Full Text

Cited By:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments

Hepatitis Monthly accepts terms & conditions of: Show

Copyright © 2019, Kowsar . CC BY-NC 4.0. All Rights Reserved.

Journal Management System. Powered by NeoScriber ® 3.33